Elagolix Sodium interactions
Checked as Elagolix in this data source.
Full monograph for Elagolix SodiumCheck it against another medicine
Medicines
244 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Ceritinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme… | 3 sources — open the full entry |
| Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme… | 3 sources — open the full entry |
| Cyclosporine (Oral) | Major | Distribution | Coadministration with potent inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of elagolix… | 14 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme… | 3 sources — open the full entry |
| Fentanyl Citrate | Major | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as… | 12 sources — open the full entry |
| Gemfibrozil | Major | Distribution | Coadministration with potent inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of elagolix… | 14 sources — open the full entry |
| Itraconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme… | 3 sources — open the full entry |
| Ketoconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme… | 3 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme… | 3 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme… | 3 sources — open the full entry |
| Leflunomide | Major | Synergy | The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may… | 3 sources — open the full entry |
| Lopinavir + Ritonavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme…2 documented mechanisms | 8 sources — open the full entry |
| Mavacamten | Major | Metabolism | Coadministration with inhibitors of CYP450 2C19 that can also induce CYP450 3A4 may alter the plasma concentrations of mavacamten. | 1 sources — open the full entry |
| Morphine Sulfate | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of morphine and its risk of adverse effects, including… | 7 sources — open the full entry |
| Nelfinavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme… | 3 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme…2 documented mechanisms | 4 sources — open the full entry |
| Posaconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme… | 3 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme… | 3 sources — open the full entry |
| Relugolix | Major | Absorption · Synergy | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 5 sources — open the full entry |
| Relugolix + Estradiol + Norethindrone | Major | Absorption · Metabolism · Synergy | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the…3 documented mechanisms | 58 sources — open the full entry |
| Rifampicin | Major | Metabolism | Coadministration with rifampin may significantly increase the plasma concentrations of elagolix. The proposed mechanism is inhibition of organic anion… | 1 sources — open the full entry |
| Rifampicin + Isoniazid | Major | Metabolism | Coadministration with rifampin may significantly increase the plasma concentrations of elagolix. The proposed mechanism is inhibition of organic anion… | 1 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | Major | Metabolism | Coadministration with rifampin may significantly increase the plasma concentrations of elagolix. The proposed mechanism is inhibition of organic anion… | 1 sources — open the full entry |
| Vonoprazan + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme…2 documented mechanisms | 5 sources — open the full entry |
| Voriconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elagolix, which is a substrate of the isoenzyme… | 3 sources — open the full entry |
| Abemaciclib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of abemaciclib and its pharmacologically active metabolites, all of which… | 2 sources — open the full entry |
| Abiraterone Acetate | Moderate | Metabolism | Coadministration with inhibitors of the OATP 1B1 hepatic uptake transporter, CYP450 3A4 metabolic isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter… | 1 sources — open the full entry |
| Acalabrutinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of acalabrutinib, which is primarily metabolized by the isoenzyme. | 2 sources — open the full entry |
| Afatinib Dimaleate | Moderate | Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Alpelisib | Moderate | Metabolism | Coadministration of alpelisib with inducers of CYP450 3A4 may reduce the plasma concentrations of alpelisib. The proposed mechanism, based on in vitro data, is… | 2 sources — open the full entry |
| Ambrisentan | Moderate | Others | Coadministration with elagolix may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 2 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of atorvastatin and its active metabolites, all of which are substrates of… | 12 sources — open the full entry |
| Apalutamide | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of elagolix, which is a substrate of both the… | 1 sources — open the full entry |
| Apixaban | Moderate | Others | Coadministration with elagolix may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 2 sources — open the full entry |
| Apremilast | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of apremilast, which is primarily metabolized by the isoenzyme in vitro. | 1 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with inhibitors of the OATP 1B1 hepatic uptake transporter, CYP450 3A4 metabolic isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter… | 1 sources — open the full entry |
| Aripiprazole | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of aripiprazole, which is partially metabolized by the isoenzyme. | 10 sources — open the full entry |
| Armodafinil | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of elagolix, which is a substrate of both the… | 1 sources — open the full entry |
| Artemether + Lumefantrine | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by…2 documented mechanisms | 19 sources — open the full entry |
| Artesunate | Moderate | Others | Coadministration with elagolix may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed… | 2 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of atorvastatin and its active metabolites, all of which are substrates of… | 12 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of atorvastatin and its active metabolites, all of which are substrates of… | 12 sources — open the full entry |
| Avanafil | Moderate | Metabolism | Theoretically, coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of avanafil, which is primarily metabolized by the isoenzyme. | 10 sources — open the full entry |
| Axitinib | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme. | 3 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Metabolism | Coadministration with inhibitors of the OATP 1B1 hepatic uptake transporter, CYP450 3A4 metabolic isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter…3 documented mechanisms | 5 sources — open the full entry |
| Betamethasone + Clotrimazole | Moderate | Metabolism | Coadministration with inhibitors of the OATP 1B1 hepatic uptake transporter, CYP450 3A4 metabolic isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter… | 1 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Moderate | Metabolism | Coadministration with inhibitors of the OATP 1B1 hepatic uptake transporter, CYP450 3A4 metabolic isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter… | 1 sources — open the full entry |
| Betrixaban | Moderate | Absorption | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of betrixaban, which is a substrate of the efflux transporter. | 4 sources — open the full entry |
| Bicalutamide | Moderate | Metabolism | Coadministration with inhibitors of the OATP 1B1 hepatic uptake transporter, CYP450 3A4 metabolic isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter… | 1 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | Coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of elagolix, which is a substrate of both the… | 1 sources — open the full entry |
Conditions
Conditions in which Elagolix Sodium needs care, as documented in this source.
Hepatic Insufficiency
MajorCompared to women with normal liver function, those with moderate hepatic impairment had approximately 3-fold higher elagolix exposures and those with severe hepatic impairment had approximately 7-fold higher elagolix exposures. Because of these increased exposures and risk for bone loss, the use of elagolix is contraindicated in women with severe hepatic impairment (Child-Pugh C). In women with moderate hepatic impairment (Child-Pugh B) elagolix 150 mg is recommended once daily with the duration of treatment limited to 6 months. No dose adjustment is needed for women with mild hepatic impairment (Child-Pugh A).
1 source
- "Product Information. Orilissa (elagolix)." AbbVie US LLC (2018):
Osteoporosis
MajorElagolix is contraindicated in women with known osteoporosis because of the risk of further bone loss. Elagolix causes a dose-dependent decrease in bone mineral density (BMD), which is greater with increasing duration of use and may not be completely reversible after stopping treatment.
1 source
- "Product Information. Orilissa (elagolix)." AbbVie US LLC (2018):
Mental Disorders
ModerateSuicidal ideation and behavior, has been reported in women treated with elagolix in the endometriosis clinical trials. Women with a history of suicidality or depression had a higher incidence of depression compared to women without such a history. Promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits. Patients with new or worsening depression, anxiety or other mood changes should be referred to a mental health professional. Advise patients to seek immediate medical attention for suicidal ideation and behavior. Reevaluate the benefits and risks of continuing elagolix if such events occur.
1 source
- "Product Information. Orilissa (elagolix)." AbbVie US LLC (2018):
Therapeutic duplication
Drug classes that overlap with Elagolix Sodium, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
gonadotropin-releasing hormone a
The recommended maximum number of medicines in the 'gonadotropin-releasing hormone antagonists' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'gonadotropin-releasing hormone antagonists' category.
Example product in the source data (US market): Estradiol/norethindrone/relugolix